Boston Scientific’s CHAMPION-AF trial found the Watchman FLX left atrial appendage closure device to be statistically superior to leading blood thinners in reducing major bleeding, while matching them ...
Boston Scientific (NYSE:BSX) released new clinical trial results for its FARAPULSE PFA Platform and WATCHMAN LAAC at Heart Rhythm 2026. The AVANT GUARD trial reported superiority of FARAPULSE PFA over ...
TEMECULA – Niraj Parekh, MD, performed Southwest Healthcare Temecula Valley Hospital's first patient implant of the new WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device. The Watchman ...
Memorial Health System is celebrating a major milestone Tuesday. Dr. Umair Malik has completed over 100 Watchman procedures, helping patients reduce their risk of stroke and take control of their ...
GRAND RAPIDS – On January 26, Emma Hegwood, DO performed the first combined catheter ablation for atrial fibrillation and Watchman® left atrial appendage occlusion procedure, known as a concomitant ...
MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...
When including procedural bleeding in a secondary analysis, the WATCHMAN FLX device performance was consistent with the primary safety endpoint, demonstrating a significant reduction in bleeding ...
During the AHA Scientific Sessions 2025, a session was presented that focused on dilemmas related to antithrombotic therapy following catheter ablation in patients with AF. A session presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results